(Total Views: 296)
Posted On: 08/02/2017 9:02:58 PM
Post# of 11803
Re: nonsequetor #1563
anddddddddddddddddddddddd...
The main reason why an M&A Partner would be interested in this company, DECN...
GenPrecis® Precision Monitoring System
Designed to be the Most Accurate Home Monitoring System on the Market
This GenPrecis® Precise meter along with the GenPrecis® test strip will allow the diabetic to perform a most accurate and precise glucose test while automatically adjusting for hematocrit interference, the interference most often associated with less accurate glucose results.
http://www.pharmatechdirect.com/
In March 2017 the company was approached by its Korean partner, The Bio Co., Ltd to design and fund a
new product which the company will call GenPrecis!. This product, when completed, will represent a major
improvement in diabetic glucose monitoring. The GenPrecis! system will be the first of its kind +/- 10% system.
Current ISO (2013) and FDA (2014) guidelines call for glucose monitoring systems to meet a +/- 15% standard,
whereby the meter and strip must be within +/- 15% in repeated samplings 95% of the time. GenUltimate! and
GenChoice! are +/- 15% test strips, but in each case 97+% of the time in repeated samplings. GenPrecis! is designed
to meet the written standards of the ISO and FDA at +/- 10%, 95% of the time – effectively setting a new standard.
The company has been funding the development of this system product, and a test strip only derivative version.The
system product will be ready for testing in September 2017 and will be registered for International sale in November
2017. However, the natural market for this product will be the U.S, and Canada where precision standards are higher
for new products.
The main reason why an M&A Partner would be interested in this company, DECN...
GenPrecis® Precision Monitoring System
Designed to be the Most Accurate Home Monitoring System on the Market
This GenPrecis® Precise meter along with the GenPrecis® test strip will allow the diabetic to perform a most accurate and precise glucose test while automatically adjusting for hematocrit interference, the interference most often associated with less accurate glucose results.
http://www.pharmatechdirect.com/
In March 2017 the company was approached by its Korean partner, The Bio Co., Ltd to design and fund a
new product which the company will call GenPrecis!. This product, when completed, will represent a major
improvement in diabetic glucose monitoring. The GenPrecis! system will be the first of its kind +/- 10% system.
Current ISO (2013) and FDA (2014) guidelines call for glucose monitoring systems to meet a +/- 15% standard,
whereby the meter and strip must be within +/- 15% in repeated samplings 95% of the time. GenUltimate! and
GenChoice! are +/- 15% test strips, but in each case 97+% of the time in repeated samplings. GenPrecis! is designed
to meet the written standards of the ISO and FDA at +/- 10%, 95% of the time – effectively setting a new standard.
The company has been funding the development of this system product, and a test strip only derivative version.The
system product will be ready for testing in September 2017 and will be registered for International sale in November
2017. However, the natural market for this product will be the U.S, and Canada where precision standards are higher
for new products.
(1)
(0)
